ARTICLE | Clinical News

Huntexil pridopidine: Extension study data

September 27, 2010 7:00 AM UTC

Data from the 6-month, open-label extension of the double-blind, placebo-controlled, European Phase III MermaiHD trial in 353 patients showed that 45 mg twice-daily Huntexil was well tolerated over 12 months with no clinically meaningful changes in vital signs or ECG measurements observed. The most common adverse events were falls, Huntington's chorea, depression, dizziness, nasopharyngitis, fatigue, irritability, diarrhea, nausea and insomnia. Additionally, there was a higher incidence of Huntington's chorea in patients receiving Huntexil for 12 months (12.5%) vs. 6 months (6.2%). However, NeuroSearch said that no similar pattern was observed on the chorea subscale of the Unified Huntington's Disease Rating Scale (UHDRS), which indicates no general worsening of chorea between 6 and 12 months of treatment with Huntexil. ...